BioSpace News Archive

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency (HRD) testing in the United States.

Resverlogix Corp. (TSX: RVX) (“Resverlogix”) today announced the publication of two articles in peer-reviewed scientific journals.

Immunotherapies have successfully treated many types of cancer with the exception of advanced prostate cancer that has become resistant to treatment, known as metastatic castration-resistant prostate cancer (mCRPC).

Elixia proudly welcomes Sam Searcy as the company’s Chief Commercial Officer. Searcy will oversee activities related to marketing, enhance service offerings, expand Elixia’s national site network, maintain client customer service, strategize Elixia’s business growth and increase Elixia’s overall market share

Oxurion NV announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Translating medical research to clinical practice can take decades. In efforts to accelerate the implementation of practice-changing research results into clinical care to improve patients’ outcomes, Northwell Health’s The Feinstein Institutes for Medical Research has been chosen, among 41 other U.S. health systems nationwide, by The Patient-Centered Outcomes Research Institute to participate in its Health Systems Implementation Initiative.

Sesen Bio, Inc., announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc., at the Company’s Special Meeting of Stockholders.

Odylia Therapeutics, a nonprofit biotechnology company, announced a partnership with JEM Therapeutics, a public benefit corporation whose mission is to discover cures for rare diseases by advancing the field of gene and cell therapy.

Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions.

Medical robotics innovator Noah Medical today announced FDA clearance of the Galaxy System™.